All XRAYs
Relevance: Medium-High
Most relevant for: Women with a BRCA1 or BRCA2 mutation who have a uterus.
Study: Study: Endometrial cancer risk for people with BRCA1 and BRCA2 mutations
This study looked at how often endometrial cancer occurred in people with BRCA1 or BRCA2 mutations to better understand how BRCA mutations affect the risk of endometrial cancer. The researchers also asked whether known risk factors for endometrial cancer impact the frequency of endometrial cancer in people with BRCA1 or BRCA2 mutations. Findings from the study highlight the importance of shared conversations between patients and providers regarding risk monitoring and preventive options. (posted 10/7/25)
READ MORE ›
Relevance: High
Most relevant for: Families with a known MLH1 mutation
Study: Cancer may occur at earlier ages in later generations of families with Lynch syndrome
In families with Lynch syndrome mutations, cancer may occur at an earlier age with each generation. This study looked at the effect called anticipation in families with MLH1-associated Lynch syndrome. (Posted 10/3/25)
READ MORE ›
Relevance: High
Most relevant for: People with metastatic castration-resistant prostate cancer
Study: Combination treatment for metastatic castration-resistant prostate cancer may be especially effective for people with BRCA1 or BRCA2 mutations
This review summarizes the results of the TALAPRO2 study. It looked at how well the PARP inhibitor Talzenna (talazoparib) works for treating metastatic castration-resistant prostate cancer (mCRPC). Talzenna appears to be most effective for people with BRCA1 or BRCA2 mutations but is also effective for people with certain other mutations. (posted 9/30/25)
READ MORE ›
Relevance: Medium-High
Most relevant for: People newly diagnosed with early-stage breast cancer who have BRCA1 or BRCA2 mutations
Study: Breast cancer treatment combination and dose improves survival in people with inherited BRCA1 and BRCA2 mutations
Treatment before surgery with a combination of targeted therapy and chemotherapy resulted in longer survival for people with an inherited BRCA1 or BRCA2 mutation who have early-stage breast cancer. The study evaluated a new dosing strategy that made it possible to safely combine Lynparza (olaparib) and chemotherapy (carboplatin). (Posted 8/31/25)
READ MORE ›
Relevance: Medium-High
Most relevant for: People with breast cancer or at high-risk of breast cancer
Update: FDA in the News: FDA approvals and health information on breast cancer
This XRAY review reports new treatments approved by the FDA for early and metastatic breast cancer and educational resources about women's health. (Posted 8/4/25)
READ MORE ›
Relevance: Medium-High
Most relevant for: People with advanced, unresectable, or metastatic pancreatic cancer or NSCLC
Study: FDA approves new targeted therapy for advanced pancreatic cancer
A new treatment called Bizengri has been approved by the FDA for patients with advanced or metastatic pancreatic cancer. This treatment targets pancreatic cancer or non-small cell lung cancers that have a rare tumor mutation called an NRG1 fusion. (Posted 7/24/25)
READ MORE ›
Relevance: Medium-High
Most relevant for: People with BRCA mutation who have textured breast implants
Study: Possible link between BRCA1 and BRCA2 mutations and rare breast implant-associated lymphoma
The causes of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare cancer that develops near implants, are unknown. Results from this study suggest that people with an inherited mutation in BRCA1 or BRCA2 may be at increased risk for BIA-ALCL. However, because very few cases of BIA-ALCL occurred among participants, more research is needed to confirm or refute this finding. (Posted 7/14/2025)
READ MORE ›
Relevance: High
Most relevant for: People with advanced or metastatic breast cancer with a PIK3CA tumor mutation.
Study: New FDA approval of Itovebi, a drug that may improve treatment for certain advanced or metastatic breast cancers
About one-third of hormone receptor-positive (HR-positive), HER2-negative metastatic breast cancers have a PIK3CA tumor mutation that can increase cancer growth and lead to treatment resistance. A new targeted therapy, Itovebi (inavolisib), improved patient outcomes when combined with standard treatment. This led to the recent FDA approval of the drug. (Posted 7/3/25)
READ MORE ›
Relevance: Medium-High
Most relevant for: People of Hispanic ancestry who have pancreatic cancer or have a family history of cancer
Study: Hereditary pancreatic cancer among people of Hispanic ancestry in Mexico
This study looks at people of Mexican ancestry who have pancreatic cancer to identify mutations linked to hereditary cancer. Knowledge of a hereditary cancer mutation can inform patients and their family members about the need for additional surveillance or different treatment options. Access to genetic testing in Mexico is more limited than in the United States. This study emphasizes the importance of genetic testing for inherited cancer risk in pancreatic cancer patients in Mexico. (posted 6/25/25)
READ MORE ›
Relevance: High
Most relevant for: People with HR-positive metastatic breast cancer
Study: Enhertu shows promising results for HER2-low and HER2-ultralow metastatic breast cancer
Recent study results show that a new targeted treatment works better than standard chemotherapy for people with metastatic hormone receptor-positive breast cancers with low or ultralow HER2 status. (Posted 5/15/25)
READ MORE ›